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Abstract Agranulocytosis is a rare but serious complica-
tion of antithyroid drug therapy, and an up-to-date under-
standing of this topic is important. Both direct toxicity and
immune-mediated responses have been described as pos-
sible mechanisms. Some major susceptibility loci have
recently been identified, which may lead the diagnosis of
agranulocytosis into a genomic era. Onset is acute and
patients present with symptoms and signs of infection
together with high fever. Clinical suspicion is pivotal and
should prompt blood sampling. An absolute neutrophil
count of \500/ll in the presence of antithyroid drugs
establishes the diagnosis. The causative drug should
immediately be stopped to prevent further damage. Treat-
ment includes broad-spectrum antibiotics and granulocyte-
colony stimulation factor in selected patients. Later,
patients will need definitive treatment for hyperthyroidism,
usually with radioactive iodine or surgery. The best way to
avoid the mortality associated with antithyroid drug-in-
duced agranulocytosis is patient education.
Key Points
Agranulocytosis occurs in 0.2–0.5% of patients with
Graves’ disease receiving antithyroid drugs.
Both direct toxicity and immune-mediated responses
seem to be the cause of agranulocytosis in these
patients. Some susceptibility loci have been found to
be associated with higher risk.
High fever and sore throat are the most common
presenting signs, but patients may also be
asymptomatic.
Treatment requires immediate suspension of the
antithyroid drug and initiation of broad-spectrum
antibiotics. Hematopoietic growth factors may be
used. Definitive treatment of hyperthyroidism is
required.
Patient education is key to preventing the high
morbidity and perhaps mortality of antithyroid drug-
induced agranulocytosis.
1 Introduction
Antithyroid drug (ATD) therapy is one option for the
treatment of hyperthyroidism, together with surgery and
radioactive iodine. Long-term remission of hyperthy-
roidism can be achieved in about 50% of patients with
Graves’ disease treated with ATDs [1]. Options include
propylthiouracil, carbimazole and its active metabolite
methimazole. In clinical practice, propylthiouracil is being
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replaced by carbimazole and methimazole because their
biological half-lives are longer (1–2 h vs. approximately
3–5 h for methimazole and carbimazole, with no differ-
ences between them [2, 3]) and the risk of severe side
effects (hepatotoxicity and agranulocytosis) is lower. The
first case of ATD-induced agranulocytosis was described in
1952 by Bartels and Sjogren [4] in their series of 250 cases
of treated patients. The patient was receiving methimazole
and had previously had agranulocytosis secondary to
propylthiouracil treatment. The first death associated with
ATD therapy also dates from 1952 [5], when a patient
receiving methimazole developed high fever and dyspnea
and eventually died of bilateral pneumonia.
ATD-induced agranulocytosis is rare, but the severity of
this possibly life-threatening condition means its manage-
ment is essential to a good prognosis. We summarize the
current evidence regarding the definition, epidemiology,
risk factors, pathophysiology, clinical presentation, and
management of this clinical entity.
2 Methods
We searched PubMed for articles published from January
1952 to September 2016 using the terms ‘agranulocytosis’
and ‘antithyroid drug’ in combination with the terms
‘management,’ ‘treatment,’ and ‘therapy.’ Further relevant
published articles were identified through searches of the
authors’ personal files, in Google Scholar, and the Springer
Online Archives Collection. Articles resulting from these
searches and relevant references cited in those articles were
reviewed.
3 Definition
Neutropenia can be categorized as mild (absolute neu-
trophil count [ANC] 1000–1500/ll), moderate (ANC
500–1000/ll), or severe (ANC\ 500/ll) [6]. One impor-
tant definition to bear in mind is that severe neutropenia is
not the same as agranulocytosis: the first only refers to the
absolute number of neutrophils, whereas the latter includes
not only neutrophils but also eosinophils, basophils, and
mast cells. Nevertheless, drug-induced agranulocytosis has
been defined as ANC\ 500/ll of blood [7]. In fact, most
patients experience ANC\ 100/ll.
It is important to find a sustained causal relationship
between agranulocytosis and ATD. Be´nichou and Solal-
Celigny [8] previously reported that the following three
criteria may be used: (1) onset of agranulocytosis during
treatment or within 7 days of previous exposure to the same
drug and complete recovery with ANC[ 1500/ll within 1
month of discontinuation of the drug; (2) recurrence of
agranulocytosis upon re-exposure to an offending drug
(rarely seen, because of the high risk of mortality); and (3)
criteria of exclusion: any history of congenital neutropenia
or immune neutropenia; recent infectious disease (partic-
ularly recent viral infection); recent chemotherapy, radio-
therapy, or immunotherapy; and an underlying
hematological disease. Another important concept is that
an ANC \ 1000/ll may be normal, as in benign ethnic
neutropenia [9]. Ethnic groups such as Sephardic and
Falasha Jews, Black Bedouin Arabs and some people of
African origin may present with such values and still be
considered within the normal range.
4 Epidemiology
Agranulocytosis is estimated to occur in 0.2–0.5% of
patients with Graves’ disease receiving ATDs [10].
A Dutch study by Van der Klauw et al. [11] reported a
relative risk of agranulocytosis of 115 (95% confidence
interval [CI] 90.5–218.6) for patients receiving ATDs,
which was the highest risk among all evaluated pharma-
cological agents. Despite the higher risk usually associated
with propylthiouracil, Tajiri et al. [12], who studied 15,398
Japanese patients with Graves’ disease, found no difference
in incidence of agranulocytosis between patients receiving
propylthiouracil and those receiving methimazole. In the
largest published series of ATD-induced agranulocytosis,
which included 754 cases [10], the mean age of onset was
43.4 ± 15.2 years, nearly 45% of patients were aged in
their 40s and 50s and females were more affected than
males (6.3: 1 ratio). When compared with untreated
patients with Graves’ disease, those with agranulocytosis
were older (p\ 0.001) and more likely to be female
(p\ 0.0001). A more recent review that included 114
patients with ATD-induced agranulocytosis diagnosed in a
single Chinese center revealed a higher female-to-male
ratio (10.4:1) and similar age of onset (41.7 ± 12.3 years)
[13].
5 Pathophysiology
In general, two mechanisms can explain why ATD-induced
agranulocytosis develops (Fig. 1) [14]. Some drugs have
the potential to be oxidized to reactive metabolites by
neutrophils, thus inducing an immune response by acti-
vating inflammasomes, thus destroying neutrophils-direct
toxicity. Accumulation of ATDs in neutrophils has been
demonstrated, favoring this hypothesis [15]. These reac-
tions are mediated by myeloperoxidase, which appears
early in granulocyte development during hematopoiesis.
The oxidative process can also be accomplished by
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cytochrome P450 (CYP); in fact, this may be the clue to
why some drugs that cause neutropenia or agranulocytosis
can also cause liver toxicity. Immune mechanisms also
seem to have a role in pathogenesis, as previously docu-
mented with positive lymphocyte transformation tests [16].
Circulating antibodies against differentiated granulocytes
may be responsible for propylthiouracil-induced agranu-
locytosis, rendering this process immune mediated [17].
These antibodies, which can be anti-neutrophil cytoplasmic
antibodies (ANCA), react against specific granules inside
the neutrophils when they migrate to the cell membrane,
inducing apoptosis. These antibodies can also react with
myeloid progenitor cells [17] and induce opsonization of
neutrophils, mediated by the complement system [16].
After identifying a genetic background in other drug-
induced side effects, Chen et al. [18] demonstrated that
human leukocyte antigen (HLA)-B*38:02 and HLA-
DRB1*08:03, both by direct HLA genotyping and genome-
wide association studies, were independent major suscep-
tibility loci (odds ratio [OR] 21.48; 95% CI 11.13–41.48
for HLA-B*3802 carriers; OR 6.13; 95% CI 3.28–11.46 for
HLA-DRB1*08:03; and OR 48.41; 95% CI 21.66–108.22
for those with both alleles). Furthermore, Cheung et al. [19]
found that HLA-B*380201 was strongly associated with
carbimazole/methimazole agranulocytosis (OR 265.5; 95%
CI 27.9–2528.0) but not with propylthiouracil. These
alleles seem to be more prevalent in Asian than in Euro-
pean populations [20], which raises the possibility of
structurally similar alleles being responsible for suscepti-
bility in non-Asian populations. Hallberg et al. [21]
addressed this question in a Caucasian population,
demonstrating an association between ATD-induced
agranulocytosis and HLA-B*27:05 and other single
nucleotide polymorphisms on chromosome 6.
6 Clinical Presentation
Agranulocytosis usually develops in the first 3 months after
ATD therapy is initiated [10], but cases after 5 days up to
more than 10 years of exposure have also been described
[22]. This difference in time of onset may be related to the
disease mechanism, with the immune-mediated process
leading to a more rapid destruction of neutrophils as
opposed to direct toxicity. The mean duration of treatment


















Fig. 1 Mechanisms behind the onset of antithyroid drug-induced
agranulocytosis. a Direct toxicity: the oxidative process of the
antithyroid drug is mediated by myeloperoxidase and cytochrome
P450, generating reactive metabolites that will induce apoptosis either
directly or via inflammasomes. b Immune-mediated toxicity: anti-
neutrophil cytoplasmic antibodies may react against neutrophil
antigens as proteinase 3, myeloperoxidase, and cathepsin G after
neutrophils are primed and antigens migrate to the cell membrane.
Anti-neutrophil cytoplasmic antibodies can also induce opsonization
of neutrophils mediated by the complement system and react with
myeloid precursors. ANCA anti-neutrophil cytoplasmic antibodies,
CYP cytochrome P450, MPO myeloperoxidase
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needed to cause agranulocytosis was found to be 36, 41,
and 42 days, respectively [23]. Agranulocytosis can man-
ifest not only after the first treatment with ATD but also in
later courses. It can manifest up to eight courses later (with
either the same or a different ATD) but usually occurs 5
months after finishing the previous treatment [24].
Symptoms of ATD-induced agranulocytosis do not dif-
fer from those of other causes of agranulocytosis. High
fever and sore throat are the most frequent signs. Acute
pharyngitis and other infections in the oral cavity are the
most common clinical diagnoses at presentation [25].
Clinical symptoms of other infections (e.g., severe pneu-
monia, anorrectal or skin infections) may also develop.
Sepsis should be suspected, particularly if fever, chills and
prostration present suddenly. Despite the typical presenta-
tion of fever, 15% of patients can be asymptomatic [16],
although they can become symptomatic shortly after
diagnosis [12].
Patients with ATD-induced agranulocytosis usually
show other signs and symptoms that differ from other
causes of agranulocytosis but are related to the thyrotoxic
state (tachycardia, tremor, anxiety and pulsatile goiter).
7 Diagnosis and Treatment
Diagnosis is established by an ANC\ 500/ll in the context
of the clinical picture presented above. Bone marrow
examination may be performed to exclude malignancy, to
determine cellularity and to assess myeloid maturation.
Features include selective reduction or absence of granu-
locytic precursors with normal or increased erythropoiesis
and megakaryocyte proliferation or left-shifted granu-
lopoiesis with few or no mature granulocytes beyond
myelocytes [26].
Treatment starts with the identification and immediate
discontinuation of the causative agent to prevent further
damage (Fig. 2). Intravenous broad-spectrum antibiotics
are the mainstay of treatment, initiated soon after blood,
urine and other samples are cultured. Hospitalization is
usually required to monitor development and administer
intravenous therapy. Preventive measures are recom-
mended, including good hygiene in high-risk areas such as
the mouth, skin and perineum. The mean time between
onset of acute agranulocytosis and normalization of ANC
with propylthiouracil, carbimazole, and methimazole are
10, 8, and 10 days, respectively [23].
Hematopoietic growth factors such as granulocyte-col-
ony stimulation factors (G-CSFs) may be used in ATD-
induced agranulocytosis and expert opinion from a hema-
tologist should be sought. The use of G-CSF has been
shown to reduce the time to hematological recovery,
duration of antibiotic therapy and hospitalization and glo-
bal costs [27, 28]. However, these results should be con-
sidered with caution as Fukata et al. [29] conducted a
prospective randomized study on the use of G-CSF and
found no improvement in recovery time in moderate and
severe agranulocytosis. A recent retrospective study repli-
cated these results [13]. A possible explanation for this
failure might be an inappropriate dose of G-CSF [30]. In
fact, their effectiveness is lower when ANC reduction is
severe [31] and the bone marrow shows an absence of
granulocytic precursors [26].
The reason for initial prescription of the ATD should not
be forgotten. In fact, during recovery from agranulocytosis,
the patient will continue to have hyperthyroidism. Alterna-
tiveways to treat the hyperthyroid state should be prescribed,
because a cross-reaction between carbimazole and propy-
lthiouracil was observed in 15.2% of patients [32]. There-
fore, surgery or radioactive iodine seem to be effective
options to restore an euthyroid state. In fact, radioactive
iodine was demonstrated as a successful option, with 88.8%
of patients experiencing euthyroidism after treatment [13].
8 Prevention
The onset of ATD-induced agranulocytosis may be abrupt,
with one patient in the case series by Nakamura et al. [10]
having a normal ANC in the previous day. This fact stands
against the need for periodic routine measurements, as this
might not be cost effective. However, as Tajiri et al. [12]
reported, this is the best method to diagnose asymptomatic
patients. A standardized approach with granulocyte count
examination at each visit was shown to correctly diagnose














Daily monitoring of total blood count until granulocyte count recovers
4
Fig. 2 Flowchart of the treatment of antithyroid drug-induced agranulocytosis. ATD antithyroid drug, iv intravenous, RAI radioactive iodine
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granulocytopenia, respectively, with no or minimum
infection symptoms [33]. On balance, one should try to
avoid the most severe and yet unpredictable outcome and
thus continue with routine measurements. However, this is
still under debate.
The best preventive measure remains patient education at
time of prescription and there is still a great margin for
improvement in this area. Robinson et al. [34] reported that
60.9% of patients were not aware of the common symptoms
of agranulocytosis and 30% of the patients who recalled
having received some education on the topic classified this
information as ‘‘poor’’. As delay in diagnosis can increase
the risk of mortality, it is essential that the patient seeks
medical help soon after the onset of initial symptoms.
9 Conclusion
From the physician’s viewpoint, this serious side effect should
be considered in every patient prescribed with any ATD who
presents with high fever and other signs of infection. From the
patient’s perspective, medical help should be sought imme-
diately after initial symptoms, because a blood cell count with
an ANC\500/ll is diagnostic and should prompt the correct
approach described above. This is why patient education at
time of prescription must not be underestimated and struc-
tured programs should be implemented. Recent knowledge
about the genetic background of this entity may be important
in the future, enabling the identification of the risk alleles in
populations with a high prevalence, a tighter granulocyte
countmeasuring in selectedpatients and the choiceof themost
appropriate treatment option.
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